From October 1, 2021 to October 31, 2021, the company has repurchased 273,210 shares, representing 0.19% for $9.5 million. With this, the company has completed the repurchase of 22,250,346 shares, representing 15.7% for $550 million under the buyback announced on November 4, 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.92 USD | -3.43% | -3.24% | +18.83% |
22/05 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
07/05 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.83% | 5.79B | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on November 4, 2019.